Updates

The landmark indication is supported by a couple of pivotal trials assessing dupilumab for patients with chronic rhinosinusitis with nasal polyps, as well as a pediatric severe asthma trial assessing the biologic.

A new study suggests an early AI-powered algorithm could help accurately identify common movements exhibited by children with autism spectrum disorder.

Biogen's Phase 2/3 study showed a higher dose of nusinersen improves motor function in SMA infants, with plans for regulatory submission to advance treatment.

Andrew Dauber, MD, MMSc, of Children's National Hospital joined us to discuss potential advantages of LUM-201 as it goes through the clinical pipeline.